Drugs · acquisition-cost intelligence
risperidone
· ingredient risperidone· RISPERIDONE 1 mg/1; RISPERIDONE .25 mg/1; RISPERIDONE 2 mg/1; RISPERIDONE 3 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.05224
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 7 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other risperidone products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| risperidone | $0.49161 | +$0.43940 |
| Risperidone | $1.14 | +$1.09 |
| RISPERDAL CONSTA | $866.29 | +$866.24 |
| PERSERIS | $2421.08 | +$2421.03 |
Medicare Part D coverage · CY2026
On 328 plan formularies · typical tier 2
Prior auth 0% · Step therapy 0% · Quantity limit 47% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.